Intermittent high-dose vitamin C therapy in patients with HTLV-I-associated myelopathy
Kataoka, A.; Imai, H.; Inayoshi, S.; Tsuda, T.
Rinsho Shinkeigaku 33(3): 282-288
1993
ISSN/ISBN: 0009-918X PMID: 8334790 Document Number: 420634
The efficacy of intermittent high-dose vitamin C therapy was evaluated in seven patients with HTLV-I-associated myelopathy (HAM). All HAM patients responded well to this therapy without serious side effects. Grade of disability score improved at 9.7 (SD 5.8) months after the therapy from 7.1 (3.3) to 3.6 (2.0) (p lt 0.01). Serum immunosuppressive acidic protein was elevated before and decreased after the therapy from 747 (316) to 398 (86) mu-g/ml (p lt 0.05), suggesting favorable immunomodulatory action of vitamin C therapy in HAM patients.